Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Argos Therapeutics
ClinicalTrials.gov Identifier:
NCT01069809
First received: February 16, 2010
Last updated: September 23, 2013
Last verified: September 2013

February 16, 2010
September 23, 2013
July 2010
April 2014   (final data collection date for primary outcome measure)
Compare the anti-HIV effects of AGS-004 versus Placebo as measured by new HIV Viral Load setpoint after a 12 week Analytical Treatment Interruption [ Time Frame: 38 weeks ] [ Designated as safety issue: No ]
Compare AGS-004's and Placebo's anti-HIV effects of AGS-004 as measured by new HIV Viral Load setpoint after a 12 week Analytical Treatment Interruption [ Time Frame: 38 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01069809 on ClinicalTrials.gov Archive Site
  • Evaluate AGS-004 versus Placebo for change in plasma HIV Viral Load levels from the value just before initiation of ART to the value at the end of the 12 week ATI. [ Time Frame: 38 weeks ] [ Designated as safety issue: No ]
  • Evaluate AGS-004 versus Placebo for change from Baseline in CD4 T-Cell absolute and percentage values at Week 26 and at the end of Step 4 (for subjects continuing ATI) [ Time Frame: 38 weeks (62 weeks for subjects continuing ATI in Step 4) ] [ Designated as safety issue: Yes ]
  • Evaluate AGS-004 versus Placebo for effects on HIV viral kinetics during the 12 week ATI, as measured my mean or median levels of plasma HIV Viral Load; assessed throughout and at the end of Step 4 (for subjects continuing ATI) [ Time Frame: 38 weeks (62 weeks for subjects continuing ATI in Step 4) ] [ Designated as safety issue: No ]
  • Evaluate AGS-004 versus Placebo for change from Baseline in TEAEs, clinical laboratory evaluations, and clinical assessments. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Evaluate AGS-004 versus Placebo for change in inflammatory markers over treatment period and ATI [ Time Frame: 38 Weeks (62 weeks for subjects continuing ATI in Step 4) ] [ Designated as safety issue: Yes ]
  • Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline in T-cell response. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline of the extent of viral evolution. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline in the chromosomally integrated viral reservoir. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Evaluate AGS-004 versus Placebo for change in plasma HIV RNA levels from the value just before initiation of ART to the value at the end of the 12 week ATI. [ Time Frame: 38 weeks ] [ Designated as safety issue: No ]
  • Evaluate AGS-004 versus Placebo for change from baseline in CD4 absolute and percentage values after 12 week ATI [ Time Frame: 38 weeks ] [ Designated as safety issue: Yes ]
  • Evaluate AGS-004 versus Placebo for effects of HIV viral kinetics during the 12 week ATI, as measured my mean or median levels of plasma HIV RNA. [ Time Frame: 38 weeks ] [ Designated as safety issue: No ]
  • Evaluate AGS-004 versus Placebo for change in baseline of TEAEs, clinical laboratory evaluations, and clinical assessments. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Evaluate AGS-004 versus Placebo for change in inflammatory markers over treatment period and ATI [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change in Baseline of T-cell response. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change in Baseline of the extent of viral evolution. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change in Baseline of chromosomally integrated viral reservoir. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption

The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
HIV Infection
  • Biological: AGS-004
    HIV-1 Immune Therapy
  • Biological: Placebo
    Inactive Placebo Injection
  • Experimental: AGS-004
    HIV-1 Immune Therapy
    Intervention: Biological: AGS-004
  • Placebo Comparator: Inactive Injection
    Inactive Placebo Injection
    Intervention: Biological: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
42
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males and females ≥ 18 to 60 years of age.
  2. HIV infection.
  3. Stable ART regimen for ≥ 3 months prior to Screening.
  4. HIV VL level ≤ 400 copies/mL for ≥ 2 months prior to Screening.
  5. HIV VL level ≤ 50 copies/mL at Screening.
  6. CD4+ T cell count ≥ 450 cells/mm3 at Screening.
  7. Pre-ART nadir CD4+ T cell counts ≥ 200 cells/mm³.
  8. Availability of an adequate sample of frozen plasma most recently collected (no more than 90 days and preferably within 30 days) before starting ART.
  9. Laboratory values within pre-defined limits at Screening and Eligibility.
  10. Negative serum pregnancy test at Screening and Eligibility for females with reproductive potential, and agreement of all subjects to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug.
  11. Able and willing to give adequate written informed consent, to communicate effectively with study personnel, and willing to be compliant with protocol requirements.

Exclusion Criteria:

  1. HIV-2 antibody positive at Screening Visit.
  2. Positive hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody (if positive HCV antibody, HCV RNA must be negative).
  3. Untreated syphilis infection (positive rapid plasma reagin [RPR]).
  4. Changes in ART regimen due to virologic breakthrough.
  5. History of lymph node irradiation or dissection.
  6. Prior use of any HIV immunotherapy or vaccine within 9 months prior to Screening.
  7. Prior participation in an AGS-004 clinical study.
  8. Treatment interruption of ART for > 1 month since starting the ART from which the pre-ART plasma sample was drawn.
  9. Any acute infection or medical illness within 14 days prior to Screening and throughout the pre-treatment evaluation phase (Step 1).
  10. Initiation of ART during the acute HIV infection stage, if date of infection known (acute infection defined as < 6 months between date of HIV infection and ART start date).
  11. Pregnancy or breast-feeding.
  12. Receipt of any immune modulators or suppressors within 30 days prior to Screening and throughout the pre-treatment evaluation phase (Step 1).
  13. Evidence of hepatic decompensation in cirrhotic subjects: history of ascites, hepatic encephalopathy, or bleeding esophageal varices, or screening laboratory results of any of the following:

    • International Normalized Ratio (INR) of ≥ 1.5 X upper limit of normal (ULN);
    • Serum albumin < 3.3 g/dL;
    • Serum total bilirubin > 1.8 X ULN, unless history of Gilbert's disease or deemed related to treatment with atazanavir.
  14. History or other clinical evidence of significant or unstable cardiac disease (e.g., angina, congestive heart failure, recent myocardial infarction, significant arrhythmia) or clinically significant electrocardiogram (ECG) abnormalities.
  15. History of moderate or severe renal impairment (i.e., persistent history of creatinine clearance < 50 mL/min) or any other renal disorder deemed clinically significant by the investigator.
  16. Prior history of an acquired immunodeficiency syndrome (AIDS) defining condition.
  17. History or other evidence of severe illness, malignancy, immunodeficiency other than HIV, or any other condition that would make the subject unsuitable for the study in the opinion of the investigator.
  18. Known allergy or sensitivity to the components of the investigational immunotherapy.
  19. Active drug or alcohol use or dependence that would interfere with adherence to study requirements in the opinion of the investigator.
  20. Use of systemic corticosteroids and use of topical steroids over a total area exceeding 15 cm² within 30 days prior to Screening.
  21. Any investigational antiretroviral agents or use of a CCR5 inhibitor at Screening.
  22. Active autoimmune disease or condition.
  23. Participation in another investigational clinical study within the previous 30 days or use of investigational agents.
  24. Body weight less than 30 kg.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT01069809
AGS-004-003, HHSN266200600019C, ES-11702
Yes
Argos Therapeutics
Argos Therapeutics
Not Provided
Principal Investigator: Jeffery Jacobson, MD Drexel University
Argos Therapeutics
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP